Emerging Company In An Emerging Market: Shenogen Aims To Combine Modern Science And TCMs
This article was originally published in PharmAsia News
Shenogen is a startup aimed at discovery and development of small molecule and biologic drugs targeted at a novel estrogen receptor (ER) variant discovered and characterized by the company. Its leading compound SNG-162 (icaritin) is in Phase II clinical trials in China.
You may also be interested in...
SEOUL - South Korean Optomagic subsidiary Chemizon signed a drug development cooperation agreement with China's Shenogen Pharma Group for small molecule therapeutics targeting modulators of the estrogen receptor alpha 36
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.